新药奥贝胆酸治疗非酒精性脂肪性肝病进展

The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease

随着全球肥胖症的流行,非酒精性脂肪性肝病发病率逐年上升,给世界造成了极大的临床与经济负担,也严重危害了公共健康。但迄今为止没有批准的治疗非酒精性脂肪性肝病的特异性药物。目前,只有一款新药奥贝胆酸正处于基于组织学研究的大型临床3期试验中。最新研究发现,奥贝胆酸展现出了优越的治疗效果,可以显著改善脂肪肝患者的肝纤维化程度,但该药物也表现出了一定的副作用,现就奥贝胆酸治疗非酒精性脂肪性肝病的现状综述如下。

With the global epidemic of obesity, the incidence of non-alcoholic fatty liver disease is increasing year by year, bringing a huge clinical and economic burden to the world and seriously endangering public health. So far, there are no approved specific drugs for the treatment of non-alcoholic fatty liver disease. At present, only a new drug called Obeticholic acid is in a large clinical phase 3 trial based on histological research. The latest research found that Obeticholic acid showed superior treatment effect, which can significantly improve the degree of liver fibrosis in fatty liver patients. But, the drug also showed certain side effects. The current status of Obeticholic acid for non-alcoholic fatty liver disease is reviewed as follows.